Clinical Trials Logo

Inflammatory Lung Diseases clinical trials

View clinical trials related to Inflammatory Lung Diseases.

Filter by:
  • None
  • Page 1

NCT ID: NCT01703013 Not yet recruiting - Clinical trials for Adrenal Insufficiency

The Significance of Defensin Alpha 4 in the Pathophysiology of the Adrenal Insufficiency in Inflammatory Lung Diseases

Start date: January 2013
Phase: N/A
Study type: Observational

The pathophysiology of the adrenal insufficiency of patients with critical diseases remains unclear. In a prior exploratory study investigating patients with exacerbation of chronic obstructive pulmonary disease (COPD), the investigators demonstrated a highly significant correlation between the expression level of Defensin-alpha 4 (DEFA4) mRNA in blood and the adrenal function assessed via low-dose ACTH tests. The aim of this prospective study is to demonstrate that DEFA4 measured both at the mRNA level (RT-PCR) and at the protein level (Western blot/Elisa) is a reliable biomarker for the prediction of adrenal insufficiency in inflammatory lung diseases (patients with COPD and pneumonia).

NCT ID: NCT01171768 Completed - Hemoptysis Clinical Trials

The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis

Start date: June 2008
Phase: N/A
Study type: Observational

Vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) are major mediators of angiogenesis and are induced by tissue inflammation and hypoxia. While elevated serum VEGF levels have been reported in inflammatory lung diseases, especially with hemoptysis, there was no study to evaluate the Ang-2 levels in lung inflammatory diseases according to the presence of hemoptysis, inflammatory biomarker and hypoxia.